Advanced Biomedical Technologies, Inc.
ABMT · OTC
7/31/2022 | 4/30/2022 | 1/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.01 | -0.21 | 0.51 |
| FCF Yield | -4.02% | -5.57% | -2.56% | -1.96% |
| EV / EBITDA | -108.98 | -105.74 | 90.84 | -144.98 |
| Quality | ||||
| ROIC | 8.75% | 8.72% | -11.18% | 5.44% |
| Gross Margin | 147.62% | 6,584.31% | 85.63% | 73.35% |
| Cash Conversion Ratio | 0.90 | 1.03 | -2.80 | 0.57 |
| Growth | ||||
| Revenue 3-Year CAGR | 76.39% | 77.92% | 77.78% | 144.89% |
| Free Cash Flow Growth | 13.39% | -21.04% | -68.10% | -16.56% |
| Safety | ||||
| Net Debt / EBITDA | -68.19 | -70.34 | 47.80 | -84.23 |
| Interest Coverage | -1.29 | -1.28 | 1.76 | -1.00 |
| Efficiency | ||||
| Inventory Turnover | 0.01 | 0.03 | 0.21 | 0.17 |
| Cash Conversion Cycle | -24,718.78 | -9,358.26 | -1,653.23 | 508.91 |